All In Biotech

Drug Trial Radar · NCT03737851

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Dec 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 208 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

208

Actual

Start

Dec 11, 2018

Primary completion

Aug 9, 2021

Study completion Sep 9, 2021

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Nov 13, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with relapsing Multiple Sclerosis (RMS).

Conditions

  • Multiple Sclerosis (MS)

Interventions

  • elezanumabDrug

    solution for infusion

  • placeboDrug

    solution for infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Overall Response Score (ORS) at Week 52Time frame: Week 52

Locations

49 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham - Main /ID# 204618

    Birmingham, Alabama

  • St. Josephs Hospital and Med Center /ID# 204197

    Phoenix, Arizona

  • Sutter East Bay Medical Foundation-Jordon Research and Education Dev. Inst. /ID# 204249

    Berkeley, California

  • The Research Center of Southern California /ID# 204269

    Carlsbad, California

  • Vladimir Royter MD /ID# 204392

    Hanford, California

  • UC Irvine Health /ID# 205728

    Irvine, California

  • Stanford MS Center /ID# 204283

    Palo Alto, California

  • UC Davis Health-Neurological Surgery /ID# 204188

    Sacramento, California

  • UCSF School of Medicine - Neurology /ID# 204251

    San Francisco, California

  • University of Colorado School of Medicine /ID# 204250

    Aurora, Colorado

  • Advanced Neurosciences Research, LLC /ID# 204289

    Fort Collins, Colorado

  • The University of Chicago Medical Center /ID# 205319

    Chicago, Illinois

  • Indiana Univ School Medicine /ID# 204891

    Indianapolis, Indiana

  • Rowe Neurology Institute /ID# 204391

    Lenexa, Kansas

  • The NeuroMedical Center /ID# 204253

    Baton Rouge, Louisiana

  • Ochsner Medical Center /ID# 204189

    New Orleans, Louisiana

  • Duplicate_Parexel International /ID# 204273

    Baltimore, Maryland

  • International Neurorehabilitation Institute /ID# 213332

    Lutherville, Maryland

  • Pediatric Endocrine Associates /ID# 204279

    Boston, Massachusetts

  • Michigan Institute for Neurological Disorders (MIND) /ID# 204194

    Farmington Hills, Michigan

  • Memorial Neurological Institute and Center for Multiple Sclerosis /ID# 206328

    Owosso, Michigan

  • Ridgeview Specialty Clinic Chaska - Neurology /ID# 204383

    Chaska, Minnesota

  • Washington University-School of Medicine /ID# 204388

    St Louis, Missouri

  • The MS Center for Innovations in Care at Missouri Baptist Medical Center /ID# 205433

    St Louis, Missouri

  • Cleveland Clinic Lou Ruvo Cent /ID# 204745

    Las Vegas, Nevada

  • Oklahoma Med Res. Foundation /ID# 204389

    Oklahoma City, Oklahoma

  • Providence Neurological Specialties - West /ID# 204248

    Portland, Oregon

  • Thomas Jefferson University /ID# 204281

    Philadelphia, Pennsylvania

  • Advanced Neurosciences Institute /ID# 204557

    Franklin, Tennessee

  • KCA Neurology - Franklin /ID# 204208

    Franklin, Tennessee

  • Tri-State Mountain Neurology /ID# 204252

    Johnson City, Tennessee

  • Neurology Consultants of Dallas - LBJ Fwy /ID# 204398

    Dallas, Texas

  • UT HSC Multiple Sclerosis Research Group - Houston /ID# 206418

    Houston, Texas

  • Dr. Bhupesh Dihenia, MD, PA /ID# 207839

    Lubbock, Texas

  • Central Texas Neurology Consul /ID# 204268

    Round Rock, Texas

  • Integrated Neurology Services, PLLC /ID# 204261

    Alexandria, Virginia

  • Evergreen Neuroscience Institute /ID# 204203

    Kirkland, Washington

  • Virginia Mason Medical Center /ID# 205440

    Seattle, Washington

  • Swedish MS Center /ID# 204198

    Seattle, Washington

  • University of Washington Medicine MS Center /ID# 205852

    Seattle, Washington

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.